Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ulrich. Julius, Sabine. Fischer, Ulrike. Schatz, Bernd. Hohenstein & Stefan R. Bornstein. (2013) Lipoprotein apheresis: an update. Clinical Lipidology 8:6, pages 693-705.
Read now
Read now
Mohammad Hassan Nemati & Behrooz Astaneh. (2010) Optimal management of familial hypercholesterolemia: treatment and management strategies. Vascular Health and Risk Management 6, pages 1079-1088.
Read now
Read now
Articles from other publishers (35)
Ulrike Schatz, Volker J.J. Schettler & Ulrich Julius. (2023) State of the Art: Lipoproteinapherese. DMW - Deutsche Medizinische Wochenschrift 148:08, pages e44-e54.
Crossref
Crossref
Auguste Dargent, Jean-Paul Pais de Barros, Samir Saheb, Randa Bittar, Wilfried Le Goff, Alain Carrié, Thomas Gautier, Isabelle Fournel, Anne Laure Rerole, Hélène Choubley, David Masson, Laurent Lagrost & Jean-Pierre Quenot. (2020) LDL apheresis as an alternate method for plasma LPS purification in healthy volunteers and dyslipidemic and septic patients. Journal of Lipid Research 61:12, pages 1776-1783.
Crossref
Crossref
Sergey Tselmin, Ulrich Julius, Nadine Weinert, Stefan R. Bornstein & Ulrike Schatz. (2019) Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis. Atherosclerosis Supplements 40, pages 38-43.
Crossref
Crossref
Alison Pottle, Gilbert Thompson, Mahmoud Barbir, Graham Bayly, Jaimini Cegla, Robert Cramb, Tina Dawson, Ruth Eatough, Vaishali Kale, Clare Neuwirth, Kirsty Nicholson, Jules Payne, James Scott, Handrean Soran, Shahenaz Walji, Suzanne Watkins, Hazel Weedon & Dev Borunendra Nath Datta. (2019) Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989–2017. Atherosclerosis 290, pages 44-51.
Crossref
Crossref
Firdevs Ayşenur Ekizler, Serkan Cay, Burak Acar, Bahar Tekin Tak, Elif Hande Ozcan Cetin & Ahmet Temizhan. (2019) Lipoprotein aferezi homozigot ailevi hiperkolesterolemi hastalarında ventriküler repolarizasyonu etkiler. Turkish Journal of Clinics and Laboratory.
Crossref
Crossref
Bernd Hohenstein. 2019. Critical Care Nephrology. Critical Care Nephrology
1154
1160.e2
.
Alison Pottle. 2019. Advanced Practice in Endocrinology Nursing. Advanced Practice in Endocrinology Nursing
1101
1120
.
A. Rosales, M. Muñoz, A. Madrid, S. Chocron, J. M. Hernández & G. Ariceta. (2018) Improvement of refractory pruritus after lipoprotein-apheresis in arthrogryposis-renal failure-cholestasis syndrome. Journal of Clinical Apheresis 33:3, pages 401-403.
Crossref
Crossref
S. Tselmin, G. Müller, U. Schatz, U. Julius, S.R. Bornstein & B. Hohenstein. (2017) Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia. Atherosclerosis Supplements 30, pages 209-216.
Crossref
Crossref
Wolfgang Ramlow, Heinrich Prophet & Grit Waitz. (2017) Prospective crossover study for a standardized comparison of the dextrane sulfate whole blood and plasma apheresis system in patients with cardiovascular disease and severe dyslipidemia. Atherosclerosis Supplements 30, pages 99-107.
Crossref
Crossref
C. Schmöcker, U. Kassner, A.I. Ostermann, S. Kiesler, E. Steinhagen-Thiessen, N.H. Schebb & K.H. Weylandt. (2017) Effect of different lipid apheresis methods on plasma polyunsaturated fatty acids. Atherosclerosis Supplements 30, pages 193-199.
Crossref
Crossref
Ioanna Gouni-Berthold. (2016) Erhöhte Lp(a)-Konzentrationen. CardioVasc 16:6, pages 50-53.
Crossref
Crossref
Kathryn Matney, Mary Berg, James M. Falko & Nicole L. Draper. (2016) The role of lipoprotein(a) in clotting reactions during lipoprotein apheresis—A case report. Journal of Clinical Lipidology 10:2, pages 438-442.
Crossref
Crossref
E. Groß, B. Hohenstein & U. Julius. (2015) Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run. Atherosclerosis Supplements 18, pages 226-232.
Crossref
Crossref
Juergen Graessler, Kai Schuhmann, Andrej Shevchenko, Steffi Kopprasch, Ryan Ban, Sybille Bergmann, Stefan R. Bornstein, Bernd Hohenstein & Ulrich Julius. (2015) Increasing plasma lysophosphatidylcholine levels in patients with regular dextran sulfate lipoprotein apheresis. Atherosclerosis Supplements 18, pages 170-175.
Crossref
Crossref
Steffi Kopprasch, Stefan R. Bornstein, Sybille Bergmann, Juergen Graessler & Ulrich Julius. (2015) Long-term therapeutic efficacy of lipoprotein apheresis on circulating oxidative stress parameters – A comparison of two different apheresis techniques. Atherosclerosis Supplements 18, pages 80-84.
Crossref
Crossref
J. Dittrich-Riediger, U. Schatz, B. Hohenstein & U. Julius. (2015) Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden. Atherosclerosis Supplements 18, pages 45-52.
Crossref
Crossref
Michael M. Page, Damon A. Bell, Amanda J. Hooper, Gerald F. Watts & John R. Burnett. (2014) Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Practice & Research Clinical Endocrinology & Metabolism 28:3, pages 387-403.
Crossref
Crossref
Ulrich Julius, Sabine Fischer, Ulrike Schatz, Jens Passauer & Stefan Bornstein. (2013) Why an Apheresis Center Should Offer More Than One Lipoprotein Apheresis Method. Therapeutic Apheresis and Dialysis 17:2, pages 179-184.
Crossref
Crossref
Heiner K. Berthold & Ioanna Gouni-Berthold. (2013) Hyperlipoproteinemia(a): Clinical significance and treatment options. Atherosclerosis Supplements 14:1, pages 1-5.
Crossref
Crossref
Henning Morawietz, Winfried Goettsch, Melanie Brux, Manja Reimann, Stefan R. Bornstein, Ulrich Julius & Tjalf Ziemssen. (2013) Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells. Atherosclerosis Supplements 14:1, pages 107-113.
Crossref
Crossref
U. Schatz, B. Arneth, G. Siegert, D. Siegels, S. Fischer, U. Julius & S.R. Bornstein. (2013) Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations. Atherosclerosis Supplements 14:1, pages 115-122.
Crossref
Crossref
S. Tselmin, R.N. Rodionov, G. Müller, S. Bornstein & U. Julius. (2013) Homocysteine in lipoprotein apheresis patients – Retrospective data analysis in apheresis center of a university hospital. Atherosclerosis Supplements 14:1, pages 123-128.
Crossref
Crossref
V. Lamounier-Zepter, C. Look, M. Ehrhart-Bornstein, S.R. Bornstein, S. Fischer & U. Julius. (2013) Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels. Atherosclerosis Supplements 14:1, pages 129-134.
Crossref
Crossref
M. Reimann, U. Julius, S.R. Bornstein, S. Fischer, H. Reichmann, H. Rüdiger & T. Ziemssen. (2013) Regular lipoprotein apheresis maintains residual cardiovascular and microvascular function in patients with advanced atherosclerotic disease. Atherosclerosis Supplements 14:1, pages 135-141.
Crossref
Crossref
M. Reimann, M. Peitzsch, T. Ziemssen, U. Julius & G. Eisenhofer. (2013) Metabolomic distinction of microvascular effects of lipoprotein apheresis – A pilot study. Atherosclerosis Supplements 14:1, pages 143-149.
Crossref
Crossref
J. Gräßler, S. Kopprasch, J. Passauer, S. Fischer, K. Schuhmann, S. Bergmann, G. Siegert, A. Shevchenko, S.R. Bornstein & U. Julius. (2013) Differential effects of lipoprotein apheresis by lipidfiltration or dextran sulfate adsorption on lipidomic profile. Atherosclerosis Supplements 14:1, pages 151-155.
Crossref
Crossref
U. Julius, K. Taseva, S. Fischer, J. Passauer & S.R. Bornstein. (2013) Current situation of lipoprotein apheresis in Saxony. Atherosclerosis Supplements 14:1, pages 51-55.
Crossref
Crossref
K.-P. Mellwig, E. Pulawski, D. Horstkotte & F. van Buuren. (2012) Lipid apheresis: oxidative stress, rheology, and vasodilatation. Clinical Research in Cardiology Supplements 7:S1, pages 45-49.
Crossref
Crossref
Manja Reimann, Ulrich Julius, Kristin Haink, Birgit Lippold, Sergey Tselmin, Stefan R. Bornstein, Heinz Reichmann, Heinz Rüdiger & Tjalf Ziemssen. (2010) LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients. Atherosclerosis 213:1, pages 212-217.
Crossref
Crossref
S. Tselmin, U. Julius, G. Müller, S. Fischer & S.R. Bornstein. (2009) Cardiovascular Events in Patients with Increased Lipoprotein (a) – Retrospective Data Analysis in an Outpatient Department of Lipid Disorders. Atherosclerosis Supplements 10:5, pages 79-84.
Crossref
Crossref
Manja Reimann, Silke Prieur, Birgit Lippold, Stefan R. Bornstein, Heinz Reichmann, Ulrich Julius & Tjalf Ziemssen. (2009) Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis. Atherosclerosis Supplements 10:5, pages 39-43.
Crossref
Crossref
Steffi Kopprasch, Juergen Graessler, Stefan R. Bornstein, Peter E.H. Schwarz, Sergey Tselmin, Antje Frind, Ines Poberschin & Ulrich Julius. (2009) Beyond lowering circulating LDL: Apheresis-induced changes of systemic oxidative stress markers by four different techniques. Atherosclerosis Supplements 10:5, pages 34-38.
Crossref
Crossref
Sergey Tselmin, Gerd Schmitz, Ulrich Julius, Stefan R. Bornstein, Andreas Barthel & Juergen Graessler. (2009) Acute effects of lipid apheresis on human serum lipidome. Atherosclerosis Supplements 10:5, pages 27-33.
Crossref
Crossref
Ulrich Julius, Sergey Tselmin, Sabine Fischer, Jens Passauer & Stefan R. Bornstein. (2009) The Dresden Apheresis Center – experience with LDL apheresis and immunoadsorption. Atherosclerosis Supplements 10:5, pages 12-16.
Crossref
Crossref